Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Seattle Genetics Achieves Takeda Sales Milestone | Contract Pharma

What are you searching for?

Sign in
Breaking News, Collaborations & Alliances

Seattle Genetics Achieves Takeda Sales Milestone

Will receive $5 million triggered by Adcetris sales

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Seattle Genetics, Inc. will receive a $5 million milestone payment under its Adcetris (brentuximab vedotin) collaboration with Takeda Pharmaceutical Co., triggered by Takeda’s annual sales surpassing $100 million in its territories. The milestone will be recognized as royalty revenue in 1Q14.
 
“This sales milestone, along with the recent approvals of Adcetris in Japan, Singapore and Australia, illustrate the strong commercial and regulatory progress being made by Takeda in its territories,” said Clay B. Siegall, Ph.D., president and chief executive officer at Seattle Genetics. “Through approvals and marketing authorizations in 39 countries to date and a significant clinical development program involving more than 30 clinical trials, we and Takeda are committed to bringing Adcetris to patients in need worldwide.”
 
The two companies are jointly developing Adcetris and Seattle Genetics has U.S. and Canadian commercialization rights and Takeda has rights in the rest of the world. Seattle Genetics is entitled to royalties based sales in its territory, as well as progress- and sales-based milestones for Adcetris within Takeda’s licensed territories.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics